Submitted by Anonymous (not verified) on 28 November 2023 - 16:00
Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Myasthenia Gravis, Date of authorisation: 10/08/2022, Revision: 5, Status: Authorised
Source: